JOHNSON & JOHNSON

Johnson & Johnson’s potential $20 bn sale of DePuy Synthes and RYBREVANT®’s record 34‑month median survival reshape its strategy and bispecific future.

JNJ’s FDA & EU approvals for Imaavy and Tecvayli boost rare‑anemia and uveal melanoma pipelines, driving growth, dividend strength, and investor confidence.

Johnson & Johnson’s shares soar to a 52‑week high as AI‑powered robotic bronchoscopy, EU Tecvayli approval, and strong investor sentiment signal solid growth potential.

Johnson & Johnson’s $1B Firefly Bio buy and Sail Biomed partnership accelerate oncology and CAR‑T therapies, while a $5.5B talc settlement removes legacy risk and boosts long‑term shareholder value.

Johnson & Johnson’s shares hit a record high after new IMAAVY data shows sustained efficacy in generalized myasthenia gravis, boosting analyst ratings and investor confidence.

Johnson & Johnson launches its dual‑energy ThermoCool SmartTouch™ SF platform in Europe, merging pulsed‑field and radiofrequency for precise lesions and less collateral damage.

Investors shift to Johnson & Johnson for defensive stability and growth, driven by solid fundamentals, diversified products and a booming surgical‑device market.

Johnson & Johnson Q1 earnings preview: investors eye modest revenue lift, EPS growth, and robust cash‑flow amid oncology gains and strong analyst sentiment.

Johnson & Johnson stock steadies at $241.3, eyes a $251.71 52‑week high, amid mixed institutional trades and fresh earnings forecasts.

Johnson & Johnson’s FDA‑approved ICOTYDE, the first oral IL‑23 psoriasis drug, boosts analyst sentiment and expands J&J’s dermatology portfolio, promising higher market share.